Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD
Fertility Matters For Men Too CountBoost is a prenatal for men that combines herbs such as Ashwagandha, Maca, and Mucuna pruriens
Gut Hormone Changes After Jejunoileal (JIB) or Biliopancreatic (BPB) Bypass Surgery for Morbid Obesity
The impurity was identified in all 10 samples it tested, the company said
WildingJBatterhamRDaviesMVan GaalLKandlerKKonakliKet al
As mentioned, this ultimately contributes to ATP production.(6)